Scarica l'app Stockscreener
21.08
1.84%
0.38
Dopo l'orario di chiusura:
21.08
Precedente Chiudi:
$20.70
Aprire:
$20.51
Volume 24 ore:
281.46K
Relative Volume:
2.06
Capitalizzazione di mercato:
$956.46M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+14.25%
1M Prestazione:
+49.61%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$20.25
$21.55
Intervallo di 1 settimana:
$18.00
$21.55
Portata 52W:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Nome
Maplight Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MPLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
21.08 | 939.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-21 | Iniziato | Jefferies | Buy |
| 2025-11-21 | Iniziato | Leerink Partners | Outperform |
| 2025-11-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-21 | Iniziato | Stifel | Buy |
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
Maplight Therapeutics reports third quarter financial results - marketscreener.com
MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times
MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView
MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
SETIA VISHWAS Insider Trades - Nasdaq
MapLight Therapeutics (MPLT) Stock Analysis Report | Financials & Insights - Benzinga
MPLT Interactive Stock Chart | MapLight Therapeutics, Inc. Stock - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
FOFF ERIN PENNOCK Insider Trades - Nasdaq
KROEGER CHRISTOPHER A Insider Trades - Nasdaq
MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada
MapLight Therapeutics initiated with a Buy at Stifel - MSN
Jefferies & Co Initiates Coverage on MapLight Therapeutics With Buy Rating, $32 Price Target - marketscreener.com
Morgan Stanley Initiates MapLight Therapeutics at Overweight With $34 Price Target - marketscreener.com
MPLT Analyst Forecasts - Quiver Quantitative
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners - Investing.com Canada
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential - TipRanks
Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials - TipRanks
MapLight Therapeutics stock initiated with Buy rating at Jefferies By Investing.com - Investing.com Canada
MapLight Therapeutics stock initiated with Buy rating by Stifel - Investing.com Canada
Morgan Stanley initiates MapLight Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
MapLight Therapeutics, Inc. (MPLT) Balance Sheet - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Latest Press Releases & Corporate News - Yahoo! Finance Canada
MapLight Therapeutics, Inc. share price - Capital.com
Timothy John Garnett Net Worth (2025) - GuruFocus
Erin Pennock Foff Net Worth (2025) - GuruFocus
Anatol Kreitzer Net Worth (2025) - GuruFocus
Vishwas Setia Net Worth (2025) - GuruFocus
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More - AOL.com
MapLight Therapeutics, Inc. (MPLT) stock major holders - Yahoo Finance UK
Long term debt to total assets ratio of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Biopharma financings jump 86% in October, raising $13.2B - BioWorld MedTech
Maplight Therapeutics (MPLT) 10K Form and SEC Filings 2025 - MarketBeat
Maplight Therapeutics Inc Azioni (MPLT) Dati Finanziari
Non sono disponibili dati finanziari per Maplight Therapeutics Inc (MPLT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):